Scaling and Root Planing (Periodontal Root Planing): Complete Technique Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Scaling and Root Planing (SRP) is the cornerstone non-surgical treatment for periodontitis and remains the primary therapeutic intervention recommended by the European Federation of Periodontology (EFP) S3 Clinical Practice Guideline for all stages of periodontitis. Also referred to as subgingival debridement, deep cleaning, or periodontal root planing, SRP is designed to disrupt and remove the subgingival biofilm (bacterial plaque), calculus (tartar), and bacterial endotoxins that colonise root surfaces within periodontal pockets, perpetuating the chronic inflammatory destruction of the supporting bone and ligament.

Unlike supra-gingival prophylaxis (standard hygiene scale and polish), SRP accesses below the gumline into periodontal pockets — the pathological space between the tooth root and the gum margin — to physically disrupt the structured subgingival biofilm that is protected from the patient’s oral hygiene efforts. Root surfaces in periodontitis are contaminated with lipopolysaccharide (LPS) endotoxin from Gram-negative anaerobes (principally Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola — the ‘red complex’ species) that sustain tissue inflammation even after visible calculus removal.

The procedure is typically delivered under local anaesthesia per quadrant, sextant, or in full-mouth sessions depending on the chosen protocol. It is performed by a dentist, dental therapist, or dental hygienist with periodontal training. For complex cases — particularly Stage III-IV periodontitis with deep pockets, furcation involvement, or unusual anatomy — referral to a specialist periodontist optimises outcomes.

Evidence from systematic reviews and Cochrane analyses confirms that SRP reduces mean probing pocket depths by 1.0-2.0 mm in moderate pockets (4-6 mm) and 2.0-3.0 mm in deep pockets (≥7 mm), with corresponding clinical attachment level (CAL) gains of 0.5-1.5 mm. These modest but clinically significant gains translate into markedly reduced bacterial burden, resolved inflammation, and, for most Stage I-II patients, no further need for surgical intervention.

Scaling and root planing is indicated for all forms of periodontitis, as well as certain peri-implant conditions and adjunctive situations. The specific technique and extent of instrumentation varies by condition.

• Stage I Periodontitis: Mild attachment loss (≤2 mm CAL), pockets 4 mm, no radiographic bone loss beyond the coronal third. SRP in 1-2 sessions per quadrant is typically curative in combination with excellent patient plaque control.
• Stage II Periodontitis: Moderate attachment loss (3-4 mm CAL), pockets 5-6 mm, horizontal bone loss. Full-mouth SRP over 2-4 sessions under local anaesthesia. Most patients achieve stable pockets without need for surgery following this phase.
• Stage III Periodontitis: Severe attachment loss (≥5 mm CAL), pockets ≥7 mm, furcation involvement Class II-III, vertical bone loss ≥3 mm. SRP remains the first treatment step (Step 2 in EFP cascade). At re-assessment, residual deep pockets indicate escalation to surgery.
• Stage IV Periodontitis: All features of Stage III plus masticatory dysfunction. Non-surgical SRP is completed first to control infection before any surgical, orthodontic, or prosthetic phases of comprehensive rehabilitation.
• Peri-implant mucositis: The reversible precursor to peri-implantitis — treated by professional mechanical debridement around the implant surface, using non-metal instruments (carbon fibre curettes, titanium instruments) to avoid scratching the implant surface, combined with subgingival antiseptic irrigation.
• Peri-implantitis (non-surgical phase): SRP with implant-compatible curettes and subgingival irrigation is attempted before surgical peri-implant treatment, though success rates are substantially lower than for natural teeth due to the complex macro-geometry of implant surfaces.
• Necrotising periodontal disease: Acute phase managed with gentle supra-gingival debridement (to avoid precipitating bacteraemia) before transitioning to full SRP after the acute phase resolves.

SRP is also performed as pre-surgical preparation — even when surgery is planned from the outset, completing a non-surgical phase first reduces tissue inflammation, improving surgical access and healing. It also allows identification of sites that respond to non-surgical treatment, avoiding unnecessary surgery.

Scaling and root planing is appropriate for virtually all patients with diagnosed periodontitis. There are very few absolute contraindications, but several conditions require specific precautions to ensure safe and effective treatment delivery.

Clinical eligibility criteria:

• Confirmed diagnosis of periodontitis by clinical periodontal charting (≥1 site with probing depth ≥4 mm with bleeding on probing, or ≥1 site with CAL loss ≥2 mm).
• Radiographic confirmation of bone loss correlating with clinical findings.
• Patient able to cooperate for local anaesthetic administration and the procedure duration (typically 45-90 minutes per quadrant).

Systemic precautions:

• Anticoagulant therapy: Patients on warfarin should have INR checked within 72 hours of SRP; INR ≤3.5 is acceptable for non-surgical periodontal treatment. Patients on NOACs (rivaroxaban, apixaban, dabigatran) do not require dose adjustment for SRP but the prescribing physician should be informed. Patients on dual antiplatelet therapy (aspirin + clopidogrel) — SRP proceeds without alteration but post-procedure haemostasis may require longer pressure time.
• Cardiac risk / infective endocarditis: Prophylactic antibiotics are required before SRP only for patients with high-risk cardiac conditions (prosthetic cardiac valves, history of infective endocarditis, congenital heart disease with unrepaired cyanotic lesions, or cardiac transplant with valvulopathy) per AHA/BCS guidelines. Amoxicillin 2g (or clindamycin 600 mg if penicillin allergic) is given 30-60 minutes pre-procedure.
• Bisphosphonate therapy: Intravenous bisphosphonate history requires specialist-directed care due to MRONJ risk. Oral bisphosphonate use for osteoporosis is low risk for SRP (no exposed bone); drug holiday generally not required for non-surgical treatment.
• Uncontrolled diabetes: SRP is performed in all diabetics; there is no glycaemic threshold that contraindicates SRP. However, healing may be slower and outcomes less predictable in patients with HbA1c >10%. Liaison with the patient’s physician to improve glycaemic control is recommended concurrently.
• Pregnancy: SRP is safe throughout pregnancy and is actively recommended to prevent pregnancy-related gingival exacerbation and possible adverse birth outcomes.
• Immunosuppression: Standard SRP proceeds for immunocompromised patients; antibiotic prophylaxis is considered on a case-by-case basis in consultation with the treating physician.

The efficacy of SRP depends on achieving thorough mechanical disruption of the subgingival biofilm and calculus from all root surfaces within the periodontal pocket. This is accomplished with a combination of ultrasonic scalers and site-specific hand curettes.

Ultrasonic instrumentation:

• Piezoelectric scalers (EMS Piezon, Satelec): Use linear/elliptical vibration (25,000-50,000 Hz) with a working action on both the push and pull stroke. Available with slim subgingival inserts (EMS Slimline, PS scaler tips) that penetrate to 6-9 mm depth with minimal tissue trauma. Produce a characteristic clean-feeling root surface and acoustic microstreaming of water that disrupts biofilm.
• Magnetostrictive scalers (Dentsply Cavitron): Elliptical vibration pattern (18,000-45,000 Hz); effective on all sides of the insert tip. Require higher water lavage volumes. Widely used in North America.
• Ultrasonic instruments are more efficient than hand instruments for calculus removal in deeper pockets and are gentler on root surfaces when used correctly. They are the preferred first instrument in most modern SRP protocols.

Hand curette instrumentation — Gracey curettes (site-specific):

• Gracey 1/2 and 3/4: Anterior teeth (incisors and canines), all surfaces.
• Gracey 5/6: Anterior teeth (all surfaces) and premolars — universal application for these areas.
• Gracey 7/8: Posterior teeth — facial and lingual (buccal and lingual surfaces of molars and premolars).
• Gracey 11/12: Posterior teeth — mesial surfaces. The most critical curette for the difficult-to-access mesial surfaces of molars.
• Gracey 13/14: Posterior teeth — distal surfaces. Used with a pull stroke from within the pocket, angled at 70-80° to the root surface.
• After-Five and Mini-Five Gracey variants have thinner shanks extended by 3 mm and blades 20% smaller — designed specifically for deep pockets (≥5 mm) and narrow embrasure spaces.

Treatment protocols — full-mouth disinfection vs. quadrant-by-quadrant:

• Full-Mouth Disinfection (FMD) — Quirynen Protocol: Proposed by Quirynen et al. (1995, KU Leuven), FMD completes all subgingival debridement within 24-48 hours, supplemented by subgingival chlorhexidine irrigation, tongue scraping, and chlorhexidine mouthrinse. The rationale is to prevent re-infection of treated quadrants from untreated reservoirs. Multiple systematic reviews show FMD achieves modestly superior pocket reduction (0.2-0.4 mm additional improvement) compared to quadrant-by-quadrant SRP at 6 months, though the clinical significance of this difference is debated.
• Quadrant-by-quadrant SRP: Each quadrant or sextant is treated at separate visits 1-3 weeks apart. The traditional approach — easier to schedule, allows adequate recovery time between visits, and avoids the need for extended single appointments. Clinical outcomes at 12 months are equivalent to FMD in most large RCTs.

Adjunctive subgingival antimicrobials:

• Chlorhexidine chips (PerioChip, 2.5 mg CHX): Biodegradable gelatin chips inserted into pockets ≥5 mm at the time of SRP or at SPT visits. Release chlorhexidine for 7-10 days, providing sustained antimicrobial effect. Meta-analyses show 0.3-0.5 mm additional pocket reduction beyond SRP alone.
• Doxycycline gel (Atridox, 10% doxycycline hyclate in Atrigel): Injectable subgingival slow-release antibiotic gel; solidifies in the pocket and releases doxycycline for 21 days. Studies show additional 0.5-0.8 mm pocket reduction versus SRP alone for sites ≥5 mm.
• Minocycline microspheres (Arestin 1 mg): Subgingival minocycline powder in bioresorbable microspheres; releases drug for 21 days post-application. Comparable evidence to PerioChip for moderate pockets.

Scaling and root planing is supported by the strongest evidence base of any periodontal treatment modality. Cochrane meta-analyses, systematic reviews, and multi-centre clinical trials consistently confirm significant and clinically meaningful improvements following SRP.

Pocket depth reduction:

• Moderate pockets (4-6 mm): mean reduction of 1.0-1.5 mm in probing pocket depth; mean CAL gain of 0.5-1.0 mm.
• Deep pockets (≥7 mm): mean reduction of 2.0-3.0 mm in probing pocket depth; mean CAL gain of 1.0-2.0 mm. A significant proportion of deep pockets (≥7 mm) resolve to <5 mm after SRP alone — the threshold below which surgical intervention is generally not indicated.
• These improvements are sustained at 12 months and beyond in patients who comply with SPT recalls and maintain good oral hygiene.

Microbial outcomes:

• SRP reduces total subgingival bacterial load by 10-100 fold within 4-8 weeks. Specific periodontopathogens — particularly the red complex species (P. gingivalis, T. forsythia, T. denticola) — are suppressed to below detection threshold in many treated sites.
• Microbial rebound occurs over 6-24 months from residual bacteria in untreated reservoirs (tongue, tonsils, interdental spaces), underscoring the importance of regular SPT re-debridement.

Host inflammatory response:

• Bleeding on probing — the key clinical marker of active gingival inflammation — reduces from a mean of 50-70% of sites in active disease to <10-15% of sites within 3 months of SRP, indicating resolution of active infection in the majority of treated sites.
• Systemic inflammatory markers (CRP, IL-6, TNF-alpha) measurably reduce following successful SRP, supporting the systemic health benefits of infection control.

Systemic health benefits:

• Glycaemic control: SRP reduces HbA1c by approximately 0.4% in Type 2 diabetics at 3-6 months follow-up — a clinically meaningful reduction in diabetes management terms.
• Endothelial function: Tonetti et al. (New England Journal of Medicine, 2007) demonstrated significantly improved brachial artery flow-mediated dilatation (FMD) 6 months after intensive periodontal treatment, compared to a control group receiving only supra-gingival cleaning. This demonstrates a direct cardiovascular benefit of subgingival infection resolution.

Scaling and root planing is a highly safe procedure when performed by a trained clinician. Most complications are minor and transient. Patients should nonetheless be fully informed before treatment commences.

Common, expected, transient effects:

• Post-procedural dentinal hypersensitivity: The most frequently reported side effect (experienced by 60-90% of patients). Root surfaces cleaned of calculus and contaminated cementum have exposed dentinal tubules that respond acutely to cold, heat, and osmotic stimuli. Typically peaks in severity within the first 24-72 hours and gradually resolves over 4-8 weeks. Managed with: fluoride varnish applied immediately post-SRP; desensitising toothpaste (stannous fluoride, potassium nitrate, arginine-calcium carbonate) used twice daily; avoidance of very cold or acidic foods and beverages during the healing phase. In-office bonding agents or oxalate desensitisers may be applied for persistent severe sensitivity.
• Gum soreness and tenderness: Post-procedure tenderness of 24-72 hours duration is expected; over-the-counter ibuprofen 400 mg or paracetamol 1g provides adequate relief for most patients.
• Apparent gum recession: Resolution of gingival oedema and inflammation after SRP causes an apparent reduction in gum height — teeth appear to ‘grow longer.’ This is not new recession but exposure of the actual pre-disease gum level once swelling subsides. Patients must be warned about this expected change before treatment to avoid distress or loss of confidence in treatment outcomes.
• Minor post-procedural bleeding: Oozing from the gum sulcus for 12-24 hours post-SRP is normal. Haemostasis is achieved by biting on gauze for 20-30 minutes. Significant or prolonged bleeding should be reported to the dental practice.

Uncommon or serious complications:

• Bacteraemia: SRP produces a transient bacteraemia of 30-60 minutes duration. For immunocompetent patients this is clinically insignificant. For high-risk cardiac patients (prosthetic valves, prior infective endocarditis), prophylactic antibiotics are mandatory as outlined in current guidelines.
• Root surface damage: Overaggressive root planing with hand curettes can remove excessive cementum, particularly on thin anterior root surfaces. Modern evidence favours ‘root surface debridement’ (selective removal of infected cementum) over aggressive root planing that removes all cementum indiscriminately.
• Incomplete calculus removal: Residual calculus in concavities, furcations, or below the junctional epithelium is the primary cause of incomplete pocket resolution. This is why specialist periodontists with advanced instrumentation training and experience are recommended for complex Stage III-IV cases.
• Percussion sensitivity: Temporary percussion tenderness of teeth treated with vigorous SRP; resolves within 1-2 weeks.

The post-SRP re-assessment visit is one of the most important milestones in the periodontal treatment journey. It determines whether the non-surgical phase has been sufficient or whether surgical escalation is required, and initiates the long-term supportive periodontal therapy programme.

Timing of re-assessment: The re-assessment appointment is scheduled 4-8 weeks after completion of the final SRP session (the EFP guideline recommends 8-12 weeks; many clinicians prefer 4-6 weeks). This interval allows: tissue healing and pocket reduction to reach a stable plateau; residual inflammation to resolve (allowing accurate probing); and sufficient time to evaluate patient compliance with home care improvements.

Content of the re-assessment visit:

• Full-mouth re-charting: all probing pocket depths, bleeding on probing, plaque scores, furcation grades, and mobility recorded and compared to pre-treatment baseline.
• Radiographic comparison: where a change in bone level is suspected or management of specific sites requires confirmation.
• Patient-reported outcomes: sensitivity, comfort with home care, smoking status change.
• Clinical decision-making:
  • Sites with pockets <4 mm and no bleeding: stable — enter SPT programme.
  • Sites with pockets 4-5 mm with no bleeding: acceptable response — enter SPT with monitoring.
  • Sites with pockets 4-5 mm with persistent bleeding: incomplete response — targeted re-instrumentation at SPT visits.
  • Sites with pockets ≥6 mm: non-response or residual disease — consider surgical intervention (flap access, osseous surgery, or regenerative procedure) depending on defect morphology and patient risk factors.

Supportive periodontal therapy (SPT) after SRP: Based on re-assessment findings and periodontal risk assessment (PRA, Lang & Tonetti), the recall interval is personalised:

• 3-month recall: Grade C patients, smokers, Stage III-IV at baseline, persistent bleeding at re-assessment.
• 4-month recall: Moderate-risk Grade B patients.
• 6-month recall: Low-risk, stable, Grade A, excellent oral hygiene compliance.

Each SPT visit includes re-probing of selected sites (or full-mouth charting annually), professional debridement of all sites, subgingival re-instrumentation at any sites showing reactivation (new bleeding or pocket deepening ≥2 mm), and oral hygiene reinforcement. The addition of subgingival chlorhexidine chips at SPT visits for sites with pockets ≥5 mm provides evidence-based adjunctive chemical control between appointments.

The cost of periodontic root planing varies based on the extent of disease, number of teeth and surfaces requiring treatment, provider specialisation, and geographic location. Unlike routine prophylaxis, SRP is a therapeutic procedure coded and billed differently by dental providers worldwide.

Typical cost ranges (approximate, global USD equivalent):

• Full-mouth SRP (all quadrants, 2-4 appointments): USD 600-2,500 in private dental practice; specialist periodontist typically charges USD 1,200-3,500 for complex full-mouth cases.
• Per-quadrant SRP billing (common in USA): USD 150-450 per quadrant for a total of 4 quadrants; American Dental Association (ADA) codes D4341 (4+ teeth per quadrant) and D4342 (1-3 teeth per quadrant) govern billing.
• Local anaesthesia: Often included in the SRP fee; if billed separately, USD 30-80 per quadrant.
• Adjunctive locally delivered antimicrobials:
  • Chlorhexidine chips (PerioChip): USD 40-100 per chip; typically 1 per deep pocket site.
  • Doxycycline gel (Atridox): USD 80-200 per syringe.
  • Minocycline microspheres (Arestin): USD 30-80 per unit dose.
• Supportive periodontal therapy (SPT maintenance): USD 100-350 per visit; scheduled 3-4 times per year for high-risk patients.
• Radiographic series (FMX or periodontal BW series): USD 100-300 for a full-mouth series, required for staging and re-assessment comparison.

Cost-reducing strategies:

• Dental schools: Periodontic departments at dental schools and dental hygiene schools offer SRP at 40-70% reduced cost, performed by supervised postgraduate students or dental hygiene students with specialist faculty oversight.
• NHS dental treatment (UK): Periodontic scaling is covered under NHS Band 2 treatment at a fixed charge (£70.70 in England as of 2025). Complex periodontic surgery may require NHS specialist referral or private treatment.
• Medical tourism: High-quality specialist periodontic SRP in Hungary (Budapest), India (Delhi, Mumbai, Chennai), Thailand (Bangkok), and Turkey (Istanbul) costs 30-60% less than comparable UK or US private care, with internationally accredited clinics offering full-mouth SRP packages including review appointments for USD 250-600 total.
• Dental insurance: Most dental insurance plans with ‘basic periodontal’ coverage pay 70-80% of SRP after deductible. Pre-authorisation and periodontal charting submission is typically required.

While mechanical subgingival debridement (SRP) remains the irreplaceable foundation of periodontal treatment, several technologies and pharmacological agents are used as alternatives or adjuncts in specific clinical situations.

Laser periodontal therapy:

• Er:YAG laser (2,940 nm, Erbium:YAG): The most biocompatible laser for root surface debridement, producing minimal thermal damage to cementum. Used as an adjunct to or replacement for hand curettes in pocket debridement. Cochrane review (Karlsson et al.) found Er:YAG SRP equivalent to conventional hand/ultrasonic SRP for pocket depth reduction and CAL gain. Does not outperform conventional SRP but offers an alternative for clinicians trained in its use.
• Diode laser (810-980 nm): Used primarily for pocket decontamination and surgical soft-tissue procedures. Evidence for diode laser as an adjunct to SRP shows modest additional reductions in bleeding on probing (<0.3 mm pocket reduction beyond SRP alone).
• LANAP (Nd:YAG, PerioLase MVP-7): Proprietary laser protocol delivered in two passes — first pass for biofilm disruption and targeted granulation tissue ablation; second pass for clot stabilisation. Claims of regenerative outcome (new cementum, PDL, and bone formation) in published case series. RCT evidence versus conventional SRP is limited; not yet incorporated into mainstream EFP or AAP guidelines.

Photodynamic therapy (PDT):

• Methylene blue or toluidine blue photosensitiser applied subgingivally; activated by low-power diode laser (660-820 nm) to produce reactive oxygen species that kill periodontopathogens. Meta-analyses show modest adjunctive benefit (<0.5 mm additional pocket reduction) versus SRP alone. A useful adjunct in antibiotic-resistant or recurrent disease.

Air-polishing with glycine or erythritol powder:

• Subgingival air-polishing using low-abrasion glycine or erythritol powder (Perio-Flow, EMS) delivered through a subgingival nozzle provides effective and comfortable biofilm disruption in pockets up to 9 mm depth. Studies show comparable pocket depth reduction to conventional SRP with less patient discomfort and root surface removal. Increasingly used as the primary maintenance tool at SPT visits (the EMS GUIDED BIOFILM THERAPY protocol combines air-polishing with selective ultrasonic scaling).

Systemic host modulation:

• Sub-antimicrobial doxycycline (SDD, Periostat 20 mg BD) inhibits matrix metalloproteinases (MMPs) that drive connective tissue destruction in periodontitis. FDA-approved as an adjunct to SRP for 3-9 months; provides modest additional CAL gain of 0.2-0.5 mm compared to SRP alone.
• Omega-3 fatty acids (fish oil, 3 g/day EPA/DHA) — anti-inflammatory lipid mediators; small RCTs show adjunctive reductions in gingival inflammation markers when combined with SRP.